PFE · 10-Q · 2026Q2 · Full report

Headcount / Restructuring

PFIZER INC · 2026-08-04 · Importance 64 · Surprise 42 · In source text

Pfizer announced an additional $1.0 billion of anticipated net savings from its Realigning Our Cost Base Program, bringing expected total savings to approximately $6.7 billion through 2029. The company expects approximately $2.0 billion of one-time costs through 2029 for the additional savings and has already achieved approximately $500 million of pipeline-focus and digital-capability savings for reinvestment in R&D by the end of 2026. The next phase of the Manufacturing Optimization Program is expected to produce $1.5 billion of additional savings through 2029, with approximately $4.0 billion of one-time costs, about 60% non-cash.

Key facts

• In the third quarter of 2026, Pfizer announced $1.0 billion of additional anticipated net cost savings for the Realigning Our Cost Base Program to be realized from 2027 through 2029, with one-time costs to achieve the additional savings to total approximately $2.0 billion incurred through 2029. source
• Certain significant items—Restructuring charges/credits, inventory write-offs, implementation costs and additional depreciation—asset restructuring for the three months ended June 28, 2026: $(81) million in cost of sales and $(56) million in selling expenses (pre-tax). source

Impact estimates